Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions | RxWiki

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

Overview[ - collapse ][ - ]

Purpose	This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.
Condition	Healthy
Intervention	Drug: Gabapentin tablets 800 mg
Phase	N/A
Sponsor	Ranbaxy Laboratories Limited
Responsible Party	Ranbaxy Inc.
ClinicalTrials.gov Identifier	NCT00778232
First Received	October 22, 2008
Last Updated	October 22, 2008
Last verified	October 2008

Tracking Information[ + expand ][ + ]

First Received Date	October 22, 2008
Last Updated Date	October 22, 2008
Start Date	October 2002
Estimated Primary Completion Date	November 2002
Current Primary Outcome Measures	Bioequivalence [Designated as safety issue: No]
Current Secondary Outcome Measures	Not Provided

Descriptive Information[ + expand ][ + ]

Brief Title	Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions
Official Title	A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions
Brief Summary	This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.
Detailed Description	A single oral dose of the test or the reference product was administered to 22 healthy adult human volunteers on two separate occasions under non-fasting conditions with at least a 7 day washout between the doses. Food and the fluid intake were controlled during each confinement period. Twenty two (22) healthy adult human volunteers (12 males and 10 females) were enrolled in the study. All twenty two (22) subjects successfully completed the clinical portion of the study
Study Type	Interventional
Study Phase	N/A
Study Design	Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label
Condition	Healthy
Intervention	Drug: Gabapentin tablets 800 mg
Study Arm (s)	Experimental: 1 Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited Active Comparator: 2 Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd

Recruitment Information[ + expand ][ + ]

Recruitment Status	Completed
Estimated Enrollment	22
Estimated Completion Date	November 2002
Estimated Primary Completion Date	November 2002
Eligibility Criteria	Inclusion Criteria: 1. All volunteers selected for the study will be healthy men or women 18 years of age or older at the time of dosing 2. The weight will no exceed ± 20% for the height and body frame as per desirable weight for adults - 1983 Metropolitan height and weight table 3. If female and Of Child bearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator (s), such as condoms , foams, jellies, diaphragm, intrauterine devices (IUD), or abstinence; or Is postmenopausal for at least 1 year; or Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) Exclusion Criteria: 1. volunteers with a recent history of drug or alcohol addiction or abuse 2. Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system (s) or psychiatric disease (as determined by the clinical investigators) 3. Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant 4. Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen 5. Volunteers demonstrating a positive drug abuse screen when screened for this study 6. Female volunteers demonstrating a positive pregnancy screen 7. Female volunteers who are currently breast feeding 8. Volunteers with a history of allergic response (s) to Gabapentin or related drugs 9. Volunteers with a history of clinically significant allergies including drug allergies 10. Volunteers with a clinically significant illness during the 4 weeks prior to period I dosing (as determined by the clinical investigators) 11. Volunteers who are currently using tobacco products 12. Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to period I dosing 13. Volunteers who report donating greater than 150 mL of blood within 30 days prior to period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study 14. Volunteers who have donated plasma (eg. Plasmapheresis) within 14 days prior to period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study 15. Volunteers who report receiving any investigational drug within 30 days prior to period I dosing 16. Volunteers who report taking any systemic prescription medication in the 14 days prior to period I dosing.
Gender	Both
Ages	18 Years
Accepts Healthy Volunteers	Accepts Healthy Volunteers
Contacts	Not Provided
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT00778232
Other Study ID Numbers	R01-826
Has Data Monitoring Committee	Yes
Information Provided By	Ranbaxy Inc.
Study Sponsor	Ranbaxy Laboratories Limited
Collaborators	Not Provided
Investigators	Not Provided
Verification Date	October 2008

Locations[ + expand ][ + ]